吉非替尼治疗妊娠期表皮生长因子受体突变肺腺癌：随访 5 年的病例报告。

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2025-02-20 DOI:10.1016/j.lungcan.2025.108456

Merouane Messekher , Florent Fuchs , Maliha Badr , Jean-Louis Pujol

{"title":"吉非替尼治疗妊娠期表皮生长因子受体突变肺腺癌：随访 5 年的病例报告。","authors":"Merouane Messekher , Florent Fuchs , Maliha Badr , Jean-Louis Pujol","doi":"10.1016/j.lungcan.2025.108456","DOIUrl":null,"url":null,"abstract":"<div><div>We report the case of a 37-year-old pregnant woman at 19 weeks of gestation who was diagnosed with a stage M1b <em>EFGR</em><sup>mut</sup> lung adenocarcinoma, in 2019. After a right upper and middle bilobectomy (T3N1 and R0 pathological status) and a complete cerebellar metastasis resection, she was treated with gefitinib, which offered her a prolonged recurrence-free survival without any negative consequence for the fetal development or the future development of her now 5- year- old child.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108456"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up\",\"authors\":\"Merouane Messekher , Florent Fuchs , Maliha Badr , Jean-Louis Pujol\",\"doi\":\"10.1016/j.lungcan.2025.108456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>We report the case of a 37-year-old pregnant woman at 19 weeks of gestation who was diagnosed with a stage M1b <em>EFGR</em><sup>mut</sup> lung adenocarcinoma, in 2019. After a right upper and middle bilobectomy (T3N1 and R0 pathological status) and a complete cerebellar metastasis resection, she was treated with gefitinib, which offered her a prolonged recurrence-free survival without any negative consequence for the fetal development or the future development of her now 5- year- old child.</div></div>\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":\"202 \",\"pages\":\"Article 108456\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0169500225000777\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225000777","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们报告了一例妊娠 19 周的 37 岁孕妇的病例，她于 2019 年被诊断为 M1b 期 EFGRmut 肺腺癌。在进行了右侧中上部双叶切除术（病理状态为 T3N1 和 R0）和小脑转移灶完全切除术后，她接受了吉非替尼治疗，延长了无复发生存期，且未对胎儿发育或其 5 岁孩子的未来发育造成任何负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up

We report the case of a 37-year-old pregnant woman at 19 weeks of gestation who was diagnosed with a stage M1b EFGR^mut lung adenocarcinoma, in 2019. After a right upper and middle bilobectomy (T3N1 and R0 pathological status) and a complete cerebellar metastasis resection, she was treated with gefitinib, which offered her a prolonged recurrence-free survival without any negative consequence for the fetal development or the future development of her now 5- year- old child.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.